A Barrier to Artificially High Prices
The Federal Antimonopoly Service has found a number of expensive drugs approved in Russia at artificially high prices. Most manufacturers, according to the rules introduced by a decree of the Government of the Russian Federation of September 15, 2015 No 979, decreased the prices to a minimum level in reference countries. In relation to the Pharma companies that refused to do that, FAS of Russia recalled its decision on approval of the maximum sales prices.
In particular, the Federal Antimonopoly Serivce recalled its decision on approval of price for Indian Imatinib (INN imatinib), when it turned out that false information on prices at the country of manufacture were provided: in India the drug costs almost 10 times lower, than the price specified by the manufacturer.